➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
AstraZeneca
Dow

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LGX818

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LGX818?

LGX818 is an investigational drug.

There have been 23 clinical trials for LGX818. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.

There are twenty-nine US patents protecting this investigational drug and four hundred and five international patents.

Recent Clinical Trials for LGX818
TitleSponsorPhase
BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)Merck KGaA, Darmstadt, GermanyPhase 3
BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)Ono Pharmaceutical Co. LtdPhase 3
BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)PfizerPhase 3

See all LGX818 clinical trials

Clinical Trial Summary for LGX818

Top disease conditions for LGX818
Top clinical trial sponsors for LGX818

See all LGX818 clinical trials

US Patents for LGX818

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LGX818   Start Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Compositions and methods for activating "stimulator of interferon gene"--dependent signalling ADURO BIOTECH, INC. (Berkeley, CA)   Start Trial
LGX818   Start Trial Antibody molecules to TIM-3 and uses thereof Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) Children's Medical Center Corporation (Boston, MA)   Start Trial
LGX818   Start Trial Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB)   Start Trial
LGX818   Start Trial Combination therapy Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-iso- propyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate Array BioPharma Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LGX818

Drugname Country Document Number Estimated Expiration Related US Patent
LGX818 Argentina AR077975 2029-08-28   Start Trial
LGX818 Australia AU2010286569 2029-08-28   Start Trial
LGX818 Canada CA2771775 2029-08-28   Start Trial
LGX818 Chile CL2012000340 2029-08-28   Start Trial
LGX818 China CN102725283 2029-08-28   Start Trial
LGX818 China CN103896921 2029-08-28   Start Trial
LGX818 Colombia CO6612222 2029-08-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.